Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2901 - 3000
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2901 | 26634825 |
US |
81 | 2 |
Death, Renal failure, Arthritis infective, Peripheral swelling, Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, DUPILUMAB, ORAL SEMAGLUTIDE, METOLAZONE, FERROUS SULFATE, LINAGLIPTIN, FUROSEMIDE, MONTELUKAST, CLOPIDOGREL, CLOPIDOGREL BISULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, NITROGLYCERIN, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 2902 | 26634962 |
US |
54 | 2 |
Graves^ disease, Palpitations, Pruritus, Dermatitis atopic, Pruritus, Product dose omission issue, Erythema, Skin exfoliation, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, ORAL SEMAGLUTIDE, CETIRIZINE HYDROCHLORIDE, MONTELUKAST SODIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AMLODIPINE, PROPRANOLOL HYDROCHLORIDE, |
||||
| 2903 | 26634984 |
US |
17 | 2 |
Renal haemorrhage, Constipation, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2904 | 26634999 |
US |
1 | |
Acute psychosis, Mental status changes, Depression, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2905 | 26635022 |
EU |
82 | 2 |
Dermatitis atopic, Injection site pain, Intentional dose omission, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2906 | 26635119 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2907 | 26635129 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2908 | 26635130 |
US |
19 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2909 | 26635164 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2910 | 26635166 |
US |
44 | 1 |
Dermatitis atopic, Erythema, Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2911 | 26635169 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2912 | 26635234 |
US |
1 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2913 | 26635241 |
US |
72 | 1 |
Pruritus, Skin exfoliation, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2914 | 26635243 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2915 | 26635265 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2916 | 26635312 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2917 | 26635365 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2918 | 26635371 |
US |
84 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2919 | 26635373 |
US |
58 | 1 |
Dermatitis atopic, Pruritus, Rash, Therapeutic response shortened, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2920 | 26635824 |
US |
43 | 1 |
Dermatitis atopic, Pruritus, Product dose omission issue, Disease recurrence, |
||||
DUPILUMAB, |
||||
| 2921 | 26635906 |
US |
56 | 2 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Rash, Discomfort, Eczema, Injection site pain, |
||||
DUPILUMAB, |
||||
| 2922 | 26636037 |
US |
2 | |
Dermatitis atopic, Pruritus, Hypersensitivity, Product dose omission issue, |
||||
DUPILUMAB, BIOTIN, FISH OIL, NORETHINDRONE, ERGOCALCIFEROL, |
||||
| 2923 | 26636042 |
US |
84 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2924 | 26636044 |
US |
37 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, CABOTEGRAVIR, FISH OIL, GARLIC, MAGNESIUM, PANTOPRAZOLE SODIUM, VITAMIN C, ERGOCALCIFEROL, BUPROPION HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, FISH OIL, BUPROPION HYDROCHLORIDE, VITAMIN C, |
||||
| 2925 | 26636092 |
US |
31 | 2 |
Dermatitis atopic, Pruritus, Dry skin, Skin fissures, Injection site vesicles, Injection site pain, Upper respiratory tract infection, Nasopharyngitis, Nasal congestion, Oropharyngeal pain, Eyelids pruritus, Diarrhoea, Abdominal distension, Sleep disorder due to a general medical condition, Headache, Dizziness, Rash, |
||||
DUPILUMAB, ALBUTEROL SULFATE, DICYCLOMINE HYDROCHLORIDE, ESCITALOPRAM OXALATE, ESCITALOPRAM, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, ESOMEPRAZOLE MAGNESIUM, |
||||
| 2926 | 26636094 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, CYCLOBENZAPRINE, MECLIZINE HCL 12.5 MG, MECLIZINE HCL 25 MG, MECLIZINE HYDROCHLORIDE, MECLIZINE, MECLIZINE HCL 25MG, MECLIZINE HCL 12.5MG, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 2927 | 26636109 |
US |
61 | 1 |
Arthralgia, Drug ineffective, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2928 | 26636195 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 2929 | 26636198 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, ALLOPURINOL, CARVEDILOL, CLOPIDOGREL, CLOPIDOGREL BISULFATE, OLMESARTAN MEDOXOMIL, ROSUVASTATIN CALCIUM, EZETIMIBE, |
||||
| 2930 | 26636341 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LEVONORGESTREL, ERGOCALCIFEROL, |
||||
| 2931 | 26636732 |
US |
9 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2932 | 26636796 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2933 | 26636798 |
US |
45 | 1 |
Dermatitis atopic, Rash, Erythema, |
||||
DUPILUMAB, |
||||
| 2934 | 26636803 |
US |
77 | 1 |
Dermatitis atopic, Dermatitis allergic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2935 | 26636807 |
US |
45 | 2 |
Dermatitis atopic, Rash, Pruritus, |
||||
DUPILUMAB, |
||||
| 2936 | 26636813 |
US |
30 | 2 |
Hypersensitivity, Injection site urticaria, Rash, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, PREDNISONE, |
||||
| 2937 | 26636814 |
US |
73 | 2 |
Dermatitis atopic, Therapeutic response shortened, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2938 | 26637039 |
US |
||
Vitiligo, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2939 | 26637046 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2940 | 26628648 |
CA |
61 | 2 |
Suicidal ideation, Burning sensation, Depression, Mobility decreased, Drug intolerance, Skin lesion, Drug hypersensitivity, Pruritus, Crying, Eczema, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM, |
||||
| 2941 | 26628933 |
US |
76 | |
Dermatitis atopic, Rash papular, Dry skin, Erythema, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2942 | 26629069 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2943 | 26629071 |
US |
1 | |
Discomfort, Rash, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 2944 | 26629073 |
US |
13 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2945 | 26629074 |
US |
29 | 1 |
Muscle spasms, Musculoskeletal stiffness, Dermatitis atopic, Pruritus, Skin haemorrhage, Skin weeping, Skin fissures, Dry skin, Skin exfoliation, Sleep disorder, |
||||
DUPILUMAB, |
||||
| 2946 | 26629077 |
US |
39 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2947 | 26629083 |
US |
50 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2948 | 26629123 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2949 | 26629126 |
US |
71 | 2 |
Dermatitis atopic, Rash pruritic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2950 | 26629155 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2951 | 26629245 |
US |
35 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2952 | 26629254 |
US |
66 | 2 |
Dermatitis atopic, Pruritus, Rash pruritic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2953 | 26629293 |
US |
39 | 1 |
Dermatitis atopic, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 2954 | 26629406 |
US |
16 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2955 | 26629415 |
US |
62 | 2 |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 2956 | 26629469 |
US |
26 | 1 |
Hospitalisation, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 2957 | 26629479 |
US |
60 | 1 |
Skin fissures, Skin haemorrhage, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2958 | 26629481 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2959 | 26629484 |
US |
41 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, MEPOLIZUMAB, |
||||
| 2960 | 26629488 |
US |
34 | 1 |
Eye irritation, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, TAPINAROF, |
||||
| 2961 | 26629489 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2962 | 26629490 |
US |
22 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2963 | 26629549 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2964 | 26629550 |
US |
12 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2965 | 26629559 |
US |
41 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2966 | 26629627 |
US |
1 | |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2967 | 26629632 |
US |
70 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2968 | 26629633 |
US |
49 | 1 |
Food allergy, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2969 | 26629671 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2970 | 26629699 |
US |
13 | 1 |
Dermatitis atopic, Exposure to toxic agent, |
||||
DUPILUMAB, |
||||
| 2971 | 26629701 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2972 | 26629717 |
US |
66 | 2 |
Atrial fibrillation, Dry skin, Skin exfoliation, Pruritus, Drug ineffective, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2973 | 26629729 |
US |
5 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 2974 | 26629730 |
US |
5 | 1 |
Dermatitis atopic, Therapeutic product effect incomplete, |
||||
DUPILUMAB, |
||||
| 2975 | 26629746 |
US |
43 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2976 | 26629750 |
US |
3 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2977 | 26629756 |
US |
24 | 1 |
Dermatitis atopic, Intentional dose omission, |
||||
DUPILUMAB, |
||||
| 2978 | 26629782 |
US |
31 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2979 | 26629906 |
US |
59 | 2 |
Dermatitis atopic, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 2980 | 26629916 |
US |
58 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2981 | 26629938 |
US |
13 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2982 | 26629939 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2983 | 26629944 |
US |
17 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2984 | 26629955 |
US |
6 | 2 |
Dermatitis atopic, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 2985 | 26630027 |
US |
1 | |
Dermatitis atopic, Pruritus, Product dose omission issue, Neurodermatitis, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2986 | 26630055 |
US |
47 | 2 |
Pharyngitis, Dermatitis atopic, Blister, Skin lesion, Scab, |
||||
DUPILUMAB, BIMEKIZUMAB, BUPROPION, DULOXETINE HYDROCHLORIDE, DULOXETINE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LORAZEPAM, |
||||
| 2987 | 26630060 |
US |
36 | 2 |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 2988 | 26630078 |
US |
75 | 2 |
Ocular discomfort, Asthma, Dermatitis atopic, Pruritus, Drug ineffective, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2989 | 26630082 |
US |
2 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, MUPIROCIN, MUPIROCIN CALCIUM, |
||||
| 2990 | 26630086 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, TIRZEPATIDE, |
||||
| 2991 | 26630139 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2992 | 26630163 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2993 | 26630174 |
US |
17 | 1 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2994 | 26630227 |
US |
71 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2995 | 26630351 |
US |
3 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2996 | 26630390 |
US |
2 | |
Dermatitis atopic, Pruritus, Pain, Skin disorder, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL SULFATE, CLOPIDOGREL, CLOPIDOGREL BISULFATE, LEFLUNOMIDE, ATORVASTATIN CALCIUM, MUPIROCIN, MUPIROCIN CALCIUM, SULFASALAZINE, LEVOTHYROXINE SODIUM, VALSARTAN, VALSARTAN ORAL, PYRITHIONE ZINC, |
||||
| 2997 | 26630579 |
US |
72 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2998 | 26630598 |
US |
20 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2999 | 26630603 |
US |
17 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 3000 | 26630610 |
US |
17 | 1 |
Dental operation, Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30